Prostatic Leiomyosarcoma: Case Report
DOI:
https://doi.org/10.32635/2176-9745.RBC.2024v70n1.4559Keywords:
Leiomyosarcoma, Prostatic Neoplasms/surgery, Prostatectomy, Radiotherapy, AdjuvantAbstract
Introduction: Sarcoma is a rare tumor, representing less than 0.1% of primary prostate tumors in adults. Of these, leiomyosarcoma is the most common subtype. They are generally found in advanced stages, making the prognosis unfavorable. The approach is variable, with surgery being the preferred management. Case report: Male patient, 65-year-old complaining of weak urinary stream and nocturia, presenting, upon rectal exam, a prostatic area of hardened consistency. Imaging tests revealed a large solid prostatic nodule, with transrectal biopsy showing that it was a stromal tumor with uncertain potential malignancy. He underwent radical retropubic prostatectomy, with anatomopathological and immunohistochemical examination confirming prostatic leiomyosarcoma. After surgical and adjuvant treatment, the patient evolved satisfactorily. Conclusion: Prostatic leiomyosarcoma is a rare and aggressive tumor. Generally, the prognosis is unfavorable, but it can be improved in patients with localized disease submitted to multimodal treatment.
Downloads
References
Janet NL, May AW, Akins RS. Sarcoma of the prostate: a single institutional review. Am J Clin Oncol. 2009;32(1):27-9. doi: https://doi.org/10.1097/coc.0b013e31817b6061 DOI: https://doi.org/10.1097/COC.0b013e31817b6061
Sexton WJ, Lance RE, Reyes AO, et al. Adult prostate sarcoma: the M. D. Anderson Cancer Center experience. J Urol. 2001;166(2):521-5. doi: https://doi.org/10.1016/s0022-5347(05)65974-5 DOI: https://doi.org/10.1016/S0022-5347(05)65974-5
Zazzara M, Divenuto L, Scarcia M, et al. Leiomyosarcoma of prostate: case report and literature review. Urol Case Rep. 2017;17:4-6. doi: https://doi.org/10.1016/j.eucr.2017.11.024 DOI: https://doi.org/10.1016/j.eucr.2017.11.024
Venyo AK. A review of the literature on primary leiomyosarcoma of the prostate gland. Adv Urol. 2015;2015:485786. doi: https://doi.org/10.1155/2015/485786 DOI: https://doi.org/10.1155/2015/485786
Jaouani L, Zaimi A, Al Jarroudi O, et al. Undifferentiated sarcoma: a rare tumor of the prostate. Cureus. 2023;15(6):e41056. doi: https://doi.org/10.7759/cureus.41056 DOI: https://doi.org/10.7759/cureus.41056
Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:59.
Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-57. doi: https://doi.org/10.1016/s0022-5347(17)36966-5 DOI: https://doi.org/10.1016/S0022-5347(17)36966-5
Miedler JD, Maclennan GT. Leiomyosarcoma of the prostate. J Urol. 2007;178(2):668. doi: https://doi.org/10.1016/j.juro.2007.05.036 DOI: https://doi.org/10.1016/j.juro.2007.05.036
Herawi M, Epstein JI. Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2006;30(6):694-704. doi: https://doi.org/10.1097/00000478-200606000-00004 DOI: https://doi.org/10.1097/00000478-200606000-00004
Alves LJ, Gameiro CD, Lopes SP, et al. Prostate leiomyosarcoma: a rare misleading tumor. Urology. 2019;130:13-16. doi: https://doi.org/10.1016/j.urology.2019.04.014 v DOI: https://doi.org/10.1016/j.urology.2019.04.014
Cheville JC, Dundore PA, Nascimento AG, et al. Leiomyosarcoma of the prostate. report of 23 cases. Cancer. 1995;76(8):1422-7. doi: https://doi.org/10.1002/1097-0142(19951015)76:8%3C1422::aid-cncr2820760819%3E3.0.co;2-l DOI: https://doi.org/10.1002/1097-0142(19951015)76:8<1422::AID-CNCR2820760819>3.0.CO;2-L
Downloads
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
